Other languages Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.72 ^USD	-1.02%		-9.33%	-11.23%

Apr. 16	Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	MT
Apr. 16	Transcript : Precision BioSciences, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	Apr. 16
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	Mar. 06
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	Mar. 01
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	Feb. 20
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness	Feb. 14
Precision BioSciences Announces 1-for-30 Reverse Stock Split; Shares Fall	Feb. 09
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	Jan. 09
TG Therapeutics, Inc. Announces Global License Agreement with Precision BioSciences, Inc. for the Development and Commercialization of Precision?s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases	Jan. 09
Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure	Dec. 13
Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases	Dec. 04
Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD?s The Liver Meeting 2023	Nov. 13
Precision BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
US FDA Transfers Cancer Medication Application to Imugene	23-09-28
Sector Update: Health Care Stocks Gain Premarket Wednesday	23-09-27
Precision BioSciences Says it Received Notice of Allowance for US Patent Covering Treatment for Mitochondrial Diseases	23-09-27
Precision BioSciences, Inc. Announces Management Changes	23-09-07
Sector Update: Health Care Stocks Decreasing Late Afternoon	23-08-16
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-08-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Other languages

Filters